Ciuffi M, Gentilini G, Franchi-Micheli S, Zilletti L
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy.
Biochem Pharmacol. 1994 Jun 15;47(12):2181-6. doi: 10.1016/0006-2952(94)90253-4.
Compounds derived from glucocorticoids, 21-aminosteroids, were reported to inhibit in vitro lipid peroxidation in CNS tissue. In order to evaluate the possible scavenging and/or iron chelating activities in vivo of the 21-aminosteroid U74500A (pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(5,6-bisdiethylamino)-2-pyridinyl)-1-piperazinyl)-16-methyl- , HCl (16 alpha)), the drug was administered for seven days to rats. These rats had been induced by iron-saccharate complex injection a slow process of lipid peroxidation into their right brain hemicortex. The drug was injected also to intact rats (normal rats). Seven days after the operation the extent of iron-induced lipid peroxidation in both the hemicortices and the effect of the drug, were assessed by the evaluation of lipid-soluble fluorescence and of conjugated diene formation. The assessment was performed both in vehicle (control) and in U74500A-treated rats. In the iron-injected rat groups the drug induced a significant dose-related reduction of fluorescence values. Formation of conjugated dienes showed a significant decrease when U74500A (48 mg/kg every 48 hr) was administered to cortico-cerebrally iron-injected animals. The lipid peroxidation of cortices in normal rats was evaluated as thiobarbituric acid reactant substances in both the drug-treated and the control animals. In normal rats, U74500A (48 mg/kg every 48 hr) caused a significant decrease of TBARS values, as compared to those observed in the control group. The iron content in the iron-injected hemicortices, which was evaluated by the ferrozine method, was not modified by drug treatment. U74500A appears to have in vivo antioxidant properties and not to affect the iron content in the neural tissue. An interaction of this drug with the metal, however, cannot be excluded.
据报道,源自糖皮质激素的化合物21-氨基类固醇可在体外抑制中枢神经系统组织中的脂质过氧化。为了评估21-氨基类固醇U74500A(孕甾-1,4,9(11)-三烯-3,20-二酮,21-(4-(5,6-双二乙氨基)-2-吡啶基)-1-哌嗪基)-16-甲基-,HCl(16α))在体内可能的清除和/或铁螯合活性,将该药物给大鼠连续给药7天。这些大鼠已通过注射糖精铁复合物在其右脑半皮质诱导了一个缓慢的脂质过氧化过程。该药物也注射给了完整大鼠(正常大鼠)。手术7天后,通过评估脂溶性荧光和共轭二烯的形成来评估半皮质中铁诱导的脂质过氧化程度以及药物的作用。评估在溶剂(对照)和U74500A处理的大鼠中均进行。在注射铁的大鼠组中,该药物导致荧光值出现显著的剂量相关降低。当给脑皮质注射铁的动物施用U74500A(每48小时48mg/kg)时,共轭二烯的形成显示出显著减少。在药物处理和对照动物中,正常大鼠皮质的脂质过氧化均以硫代巴比妥酸反应物物质进行评估。在正常大鼠中,与对照组相比,U74500A(每48小时48mg/kg)导致硫代巴比妥酸反应物值显著降低。通过亚铁嗪法评估的注射铁的半皮质中的铁含量未因药物治疗而改变。U74500A似乎具有体内抗氧化特性,且不影响神经组织中的铁含量。然而,不能排除该药物与金属之间的相互作用。